[Form 4] Arteris, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Arteris, Inc. (AIP) – Form 4 insider transaction summary

The filing discloses two open-market sales of Arteris common stock by Nicholas B. Hawkins, the company’s Vice President & Chief Financial Officer. Both sales were executed under a Rule 10b5-1 trading plan adopted on 20 May 2024.

• 26 June 2025: 5,638 shares sold at $10.00 per share (transaction code “S”), leaving 145,023 shares beneficially owned.
• 1 July 2025: 5,638 shares sold at a weighted-average price of $9.0806 (sales occurred between $8.72-$9.37), leaving 139,385 shares held directly.

Across both dates, Hawkins disposed of 11,276 shares—approximately 7-8% of the 150,661 shares he held before these transactions. No derivative security activity was reported. The CFO remains a significant shareholder, which can help maintain alignment with investors.

This information is useful for tracking insider sentiment and potential supply-demand effects on AIP’s share price. Because the trades were pre-planned, the negative signaling effect of insider selling may be moderated.

Positive

• Transactions executed under a pre-existing Rule 10b5-1 plan, reducing the chance of opportunistic trading concerns.
• CFO retains 139,385 shares, demonstrating continued equity alignment with shareholders.

Negative

• Insider selling by the CFO totals 11,276 shares, which can be perceived as a bearish signal.
• Sales represent about 7-8% of the executive’s prior holdings, increasing near-term share supply.

Insights

Financial Analyst

TL;DR: CFO sold 11,276 AIP shares (7-8% stake) at $9-10; modest insider selling, slightly bearish.

The two transactions amount to roughly $105k in proceeds, indicating personal portfolio diversification rather than a wholesale exit. Although insider sales often pressure share prices, the limited size relative to Hawkins’ remaining 139k-share position tempers concern. Absent earnings data, the filing alone suggests a mild negative sentiment signal, worth monitoring but not thesis-changing.

Corporate Governance Expert

TL;DR: Sales executed under a 10b5-1 plan, lowering abuse risk; governance impact neutral.

Because the trading plan was adopted well before execution (May 2024), the CFO’s actions comply with best-practice safeguards against material-non-public-information misuse. The executive still owns a meaningful equity stake, preserving incentive alignment. From a governance lens, the event is procedurally sound and should not trigger investor alarm.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hawkins Nicholas B.

(Last) (First) (Middle)

C/O ARTERIS, INC.

900 E. HAMILTON AVE., SUITE 300

(Street)

CAMPBELL CA 95008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP and Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/27/2025		S(1)		5,638	D	$10	145,023	D
Common Stock	07/01/2025		S(1)		5,638	D	$9.0806(2)	139,385	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on May 20, 2024.

2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.72 to $9.37 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Paul Alpern, as Attorney-in-Fact for Hawkins Nicholas B.	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Arteris (AIP) shares did the CFO sell?

Nicholas B. Hawkins sold 11,276 shares across two transactions.

What prices were the AIP shares sold at?

The first block was sold at $10.00 on 26 Jun 2025; the second block had a $9.0806 weighted-average on 1 Jul 2025.

How many AIP shares does the CFO still own?

After the reported sales, Hawkins directly owns 139,385 shares.

Were the insider sales under a 10b5-1 plan?

Yes. Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on 20 May 2024.

Did the filing report any derivative security activity?

No. Table II shows no derivative transactions during the reporting period.